TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04180410

Intervention type: DEVICE
Group type: OTHER
Intervention: EIT
Description: Electrical Impedance Tomography is performed before extubation, during follow-up visits of extubation and 48H after extubation. Follow-up visits are shortened in case of extubation failure.
Study: NCT00577330

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Myalgesin™ (celery seed extract, Boswellia serrata extract, Phellodendron extract)
Description: Twice daily

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Myalgesin™ (celery seed extract, Boswellia serrata extract, Phellodendron extract)
Description: Twice daily
Study: NCT03538392

Intervention type: DEVICE
Intervention: Serranator® Alto
Description: Serranator® Alto PTA Serration Balloon Catheter

Intervention type: DEVICE
Intervention: Serranator® Alto
Description: Serranator® Alto PTA Serration Balloon Catheter

Intervention type: DEVICE
Intervention: Serranator® Alto
Description: Serranator® Alto PTA Serration Balloon Catheter
Study: NCT04467541

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated Enterovirus Type 71 (EV71) Vaccine (Vero Cell)
Description: Inactivated Enterovirus Type 71 (EV71) Vaccine safety in healthy adults followed by safety and immunogenicity administered in two consecutive doses, one-month apart among children aged 6 to 71 months
Study: NCT02162745

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isotonic solution (NaCl 0.9%)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hypertonic solution (NaCl 3%)
Study: NCT03845998

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: use the three-finger method
Description: The size of the laryngeal mask airway was determined by choosing the laryngeal mask that best matched the combined widths of the patient's index, middle and ring fingers.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: use the weight-related method
Description: The size of the laryngeal mask airway was determined by the patient's weight.
Study: NCT00991172

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN475
Description: Single Subcutaneous injection dose level 1
Study: NCT03623412

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 75g oral glucose tolerance test
Description: Women with one abnormal value in the OGTT during pregnancy (minor degree of glucose intolerance) will be offered a post-partum 75g GTT (Glucose Tolerance Test), similar to that offered to women with GDM

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: 75g GTT
Description: post-partum GTT
Study: NCT00991172

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN475
Description: Single subcutaneous injection dose level 2

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Injection
Description: Placebo Subcutaneous injection
Study: NCT01205243

Intervention type: DRUG
Intervention: ZIAGEN®
Description: Basically there is no treatment allocation. Subjects who would be administrated ZIAGEN® at their physician's discretion will be enrolled. Dosage regimen will be recommended according to the prescribing information. Subjects will be enrolled consecutively.
Study: NCT03188211

Intervention type: OTHER
Group type: OTHER
Intervention: E-learning educational program
Description: A number of 10 cases of patients 65 years of age or older with AF, acutely admitted to Internal Medicine or Geriatric wards for any medical condition, will be edited into the Dr. Sim system. Diagnostic and therapeutic choices for ordinary and/or complex medical situations will be taken through the development of the simulated scenario.

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Any educational program will be delivered to clinicians assigned to control arm
Study: NCT02399878

Intervention type: DRUG
Intervention: Inspiratory oxygen
Study: NCT03631667

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-benzo[a]pyrene
Description: Oral micro-dose (50 ng) (5.4 nCi)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-benzo[a]pyrene plus phenanthrene
Description: Oral micro-dose of 50 ng (5.4 nCi) \[14C\]-benzo\[a\]pyrene plus 1250 ng phenanthrene
Study: NCT05295160

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: weight loss by very low energy diet intake which may differ in protein or carbohydrate content
Description: The anthropometric, endocrine and metabolic status is tested before, after 7 days and after 15 kg weight loss

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: weight loss by very low energy diet intake which may differ in protein or carbohydrate content
Description: The anthropometric, endocrine and metabolic status is tested before, after 7 days and after 15 kg weight loss
Study: NCT02392208

Intervention type: DRUG
Group type: OTHER
Intervention: Telavancin
Description: A single 5 mg/kg dose of telavancin is administered intravenously (IV).

Intervention type: DRUG
Group type: OTHER
Intervention: Telavancin
Description: A single 5 mg/kg dose of telavancin is administered intravenously (IV).

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Pharmacokinetic Blood Sampling
Description: Blood samples are collected to assess telavancin plasma concentrations.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Pharmacokinetic Blood Sampling
Description: Blood samples are collected to assess telavancin plasma concentrations.
Study: NCT03386058

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Temporary device deactivation
Description: Patient-controlled, temporary deactivation of implanted device
Study: NCT02778880

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Study: NCT03378219

Intervention type: DRUG
Intervention: Sarilumab SAR153191 (REGN88)
Description: Pharmaceutical form:injection Route of administration: subcutaneous
Study: NCT03645252

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vein interruption before any other surgical manipulation
Description: The pulmonary tumor-drainage vein is first exposed and punctured with a 23-gauge needle, and 7.5 ml of blood is drawn from the pulmonary vein prior to subsequent surgical manipulation for lobectomy. Collected blood is versed in a Cellsearch tube provided by the manufacturer (Menarini Silicon Biosystems, Castel Maggiore, Italy).~In the vein first group, the lobar vein is dissected and the cartridge and anvil of a vascular cartridge stapler are placed on either side of the vein. The vein is punctured above the stapler with a 23-gauge needle and 7.5 ml of blood is drawn. Finally, the vein is cut. The intervention then proceeds in the usual manner.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arteries interruption before vein interruption
Description: The pulmonary tumor-drainage vein is first exposed and punctured with a 23-gauge needle, and 7.5 ml of blood is drawn from the pulmonary vein prior to subsequent surgical manipulation for lobectomy. Collected blood is versed in a Cellsearch tube provided by the manufacturer (Menarini Silicon Biosystems, Castel Maggiore, Italy).~In the arteries before vein group, lobar arteries are first dissected and interrupted (+/- the bronchus and inter-lobar fissures). The lobar vein is then dissected and blood sample is performed as described above.
Study: NCT01277289

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 500 mg/20 ml encapsulated in erythrocytes, every month for 12 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexamethasone
Description: 500 mg/20 ml encapsulated in erythrocytes, every month for 12 months
Study: NCT02169635

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: macular buckle
Description: macular buckle with a three-armed silicone capsule
Study: NCT00537940

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: 150, 300, 450 mg/day administered orally TID, until seizure control/improvement or intolerable side effects

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin
Description: 300, 600, 1200, 2000 mg/day administered orally TID, until seizure control/improvement or intolerable side effects
Study: NCT02591407

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TAP Block
Description: This is a one time injection of Exparel in the plane between the internal oblique and transversus abdominis muscles
Study: NCT01369719

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: osveral
Description: receive 20 mg/kg daily orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desferal
Description: 40-50mg/Kg for 6 nights in each week subcutaneously
Study: NCT05868642

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: subarachnoid block
Description: subarachnoid block with levobupivacaine at different dosage for pation undergoing total hip arthroplasty

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: subarachnoid block
Description: subarachnoid block with levobupivacaine at different dosage for pation undergoing total hip arthroplasty
Study: NCT01257126

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: diclofenac potassium

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nimesulide
Study: NCT02591407

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Epidural Analgesia
Description: Epidural catheter placed prior to the operation in the standard fashion
Study: NCT04144881

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: coronary computed tomography
Description: patients randomized in this arm will perform computed coronary tomography 6 months after the index percutaneous revascularization on unprotected left main artery
Study: NCT04552119

Intervention type: DEVICE
Intervention: HEALICOIL Knotless PEEK
Description: HEALICOIL Knotless PEEK Self-Tapping HEALICOIL Knotless Non-Self Tapping

Intervention type: DEVICE
Intervention: HEALICOIL Knotless REGENESORB
Description: HEALICOIL Knotless REGENESORB Self -Tapping HEALICOIL Knotless REGENSORB Non-Self Tapping
Study: NCT04156100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGEN1223
Description: AGEN1223 is a bispecific antibody.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGEN1223 and balstilimab
Description: AGEN1223 is a bispecific antibody and balstilimab an anti-PD-1 Monoclonal Antibody.
Study: NCT00063362

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium
Description: Lithium monotherapy was initiated at 450 mg once daily and titrated slowly over three weeks to a minimum blood level of 0.5 milliequivalent /L (mEq/L).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lithium
Description: Lithium monotherapy was initiated at 450 mg once daily and titrated slowly over three weeks to a minimum blood level of 0.5 milliequivalent /L (mEq/L).
Study: NCT03548090

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Over-ground multi-directional gait training
Description: In the over-ground multi-directional gait protocol, the participant will walk 750 steps forward, 50 steps backward, and 200 side steps over level surfaces. The over ground gait training will focus on equalizing step length while performing multi-directional gait training.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Over-ground multi-directional gait training
Description: In the over-ground multi-directional gait protocol, the participant will walk 750 steps forward, 50 steps backward, and 200 side steps over level surfaces. The over ground gait training will focus on equalizing step length while performing multi-directional gait training.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Over-ground multi-directional gait training
Description: In the over-ground multi-directional gait protocol, the participant will walk 750 steps forward, 50 steps backward, and 200 side steps over level surfaces. The over ground gait training will focus on equalizing step length while performing multi-directional gait training.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Over-ground multi-directional gait training
Description: In the over-ground multi-directional gait protocol, the participant will walk 750 steps forward, 50 steps backward, and 200 side steps over level surfaces. The over ground gait training will focus on equalizing step length while performing multi-directional gait training.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Over-ground multi-directional gait training
Description: In the over-ground multi-directional gait protocol, the participant will walk 750 steps forward, 50 steps backward, and 200 side steps over level surfaces. The over ground gait training will focus on equalizing step length while performing multi-directional gait training.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Over-ground multi-directional gait training
Description: In the over-ground multi-directional gait protocol, the participant will walk 750 steps forward, 50 steps backward, and 200 side steps over level surfaces. The over ground gait training will focus on equalizing step length while performing multi-directional gait training.
Study: NCT00063362

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Description: Patients were assigned in a one to one ratio to adjunctive lamotrigine versus placebo after stratification for illness type (bipolar I versus bipolar II), historical response to lithium (response versus non-response), and length of current exposure to combination treatment with lithium and divalproex (\< 2 months versus ≥ 2 months). During Phase 2, patients were continued on the same doses of lithium and divalproex as during the open-label treatment phase and equal capsules of double-blind lamotrigine or matching placebo were gradually added per a structured dosing schedule up to a minimum dose of 150 mg and a maximum dose of 200 mg per day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Divalproex
Description: Divalproex was then initiated at 250 mg twice daily and increased slowly over five weeks to a minimum blood level of 50 μg/mL.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Divalproex
Description: Divalproex was then initiated at 250 mg twice daily and increased slowly over five weeks to a minimum blood level of 50 μg/mL.
Study: NCT00851760

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Consecutive surgery
Description: Consecutive surgery for epiretinal macular membrane and cataract extraction
Study: NCT00529191

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One out of three subjects will receive a placebo.
Study: NCT04964687

Intervention type: PROCEDURE
Intervention: Liver transplantation
Description: Liver transplantation

Intervention type: PROCEDURE
Intervention: Liver transplantation
Description: Liver transplantation
Study: NCT01519830

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron carboxymaltose (Ferinject)
Description: Intravenous iron

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% NaCl solution
Study: NCT04273386

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evaluation
Description: The study will be carried out with the method of filling the evaluation form which is printed on paper with ballpoint pen.
Study: NCT03050424

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric Carboxymaltose
Description: Ferric Carboxymaltose injectable Product

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride 0.9%
Description: Sodium Chloride 0.9%
Study: NCT05006131

Intervention type: OTHER
Intervention: Screening for pancreatic cancer
Description: Screening for pancreatic cancer using EUS or MRI
Study: NCT00870129

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI and advanced MRI sequences
Description: This is a nonrandomized study in which each patient will receive the standard clinical care (in the form of surgery, radiation therapy and/or chemotherapy), as per the treating physician. Surgical resection will be performed at the discretion of the treating Neurooncologist and/or Neurooncology Tumor Board. Advanced brain MRIs with the 2 (or, in some cases, 3) special sequences will be obtained at the time of the clinically scheduled contrast MRIs, which are usually obtained immediately prior to and 1 months±3 weeks after radiation therapy if the patient requires radiation therapy for his/her tumor. The advanced brain MRI may also be obtained before surgery for suspected or confirmed gliomas, as per the standard of care, in some patients who may or may not require radiation therapy.
Study: NCT02043392

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnamosis
Description: Single-use, sterile device enables creation of a circular compression intestinal anastomosis. Device is comprised of matched pair of self-centering rare earth magnets encased in medical grade polycarbonate. Geometry of magnets' mating surfaces applies force on inside of mated rings to produce compression necrosis of intervening intestinal walls. Lesser force on outside of mated rings produces inflammatory healing of the two co-apted intestinal walls. Internal lumen creates patency of the anastomosis to prevent intestinal obstruction during compression anastomosis creation. In 5-10 days, mated rings with necrotic tissue falls into intestinal lumen and is naturally expelled with stool, leaving a well-healed anastomosis.
Study: NCT01476501

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Randomized into 1 of 2 oral vitamin D3 softgel capsule supplementation strategies: 1) 2,000 IU/day (2 x 1,000IU/capsule each day) or 2) 40,000 IU/month (4 x 10,000IU/capsule last day of each month), for 6 months each.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Randomized into 1 of 2 oral vitamin D3 softgel capsule supplementation strategies: 1) 2,000 IU/day (2 x 1,000IU/capsule each day) or 2) 40,000 IU/month (4 x 10,000IU/capsule last day of each month), for 6 months each.
Study: NCT02933892

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac Catheterization
Description: Cardiac catheterization is a diagnostic procedure used to treat and diagnose heart conditions.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac Catheterization
Description: Cardiac catheterization is a diagnostic procedure used to treat and diagnose heart conditions.
Study: NCT03583398

Intervention type: PROCEDURE
Intervention: transcatheter aortic valve implantation, surgical aortic valve replacement
Description: Transcatheter aortic valve implantation using transaortic and transfemoral access and surgical aortic valve replacement.

Intervention type: PROCEDURE
Intervention: transcatheter aortic valve implantation, surgical aortic valve replacement
Description: Transcatheter aortic valve implantation using transaortic and transfemoral access and surgical aortic valve replacement.

Intervention type: PROCEDURE
Intervention: transcatheter aortic valve implantation, surgical aortic valve replacement
Description: Transcatheter aortic valve implantation using transaortic and transfemoral access and surgical aortic valve replacement.
Study: NCT00654186

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Revlimid
Description: 25mg daily on days 1 - 21 followed by 7 days of rest repeated every 28 days
Study: NCT04872231

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voriconazole Inhalation Powder
Description: PART A (SAD): Voriconazole Inhalation Powder (VIP) will be supplied as one to eight 10 mg capsules. Each capsule contains 10 mg of VIP and will be administered with a Plastiape RS00 Dry Powder inhaler. Doses may require multiple inhalations. All inhalations must be conducted within a 10-minute period.~SAD subjects will receive a single dose of study medication. Subjects in Cohort 1 will receive 10 mg, Cohort 2: 20 mg, Cohort 3: 40 mg, Cohort 4: 80 mg.~PART B (MAD): Voriconazole Inhalation Powder (VIP) and will be administered with a will be supplied as one to eight 10 mg capsules. Each capsule contains 10 mg of VIP and will be administered with a Plastiape RS00 Dry Powder inhaler. Doses may require multiple inhalations. All inhalations must be conducted within a 10-minute period.~MAD subjects will receive VIP BID for a total of 13 doses. Subjects in Cohort 1 will receive 10 mg BID, Cohort 2: 20 mg BID, Cohort 3: 40 mg BID, Cohort 4: 80 mg BID.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: PART A (SAD): Placebo capsules will be supplied as one to eight capsules. Each capsule contains placebo inhalation powder. The capsules will be matched for use within the provided Plastiape RS00 Dry Powder inhaler device (Model 8). Doses may require multiple inhalations through the inhaler device. All inhalations must be conducted within a maximum of 10-minute period.~Subjects in PART A will receive a single dose of placebo.~PART B (MAD): Placebo will be supplied as one to eight capsules. Each capsule contains placebo inhalation powder. The capsules will be matched for use within the provided Plastiape RS00 Dry Powder inhaler device (Model 8). Doses may require multiple inhalations through the inhaler device. All inhalations must be conducted within a maximum of 10-minute period.~Subjects in PART B will receive Placebo BID for a total of 13 doses.
Study: NCT01586039

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Visible light
Description: We will compare the effects of two light sources, equated for visual stimulus (lux), on multiple non-visual responses to light including melatonin suppression before bedtime. We will compare a 90 lux exposure of a commercially available Compact Fluorescent Light (CFL) with a novel LED white light source that is depleted in the short-wavelength visible range (Biological Illumination LCC, FL).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Visible light
Description: We will compare the effects of two light sources, equated for visual stimulus (lux), on multiple non-visual responses to light including melatonin suppression before bedtime. We will compare a 90 lux exposure of a commercially available Compact Fluorescent Light (CFL) with a novel LED white light source that is depleted in the short-wavelength visible range (Biological Illumination LCC, FL).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Visible light
Description: We will compare the effects of two light sources, equated for visual stimulus (lux), on multiple non-visual responses to light including melatonin suppression before bedtime. We will compare a 90 lux exposure of a commercially available Compact Fluorescent Light (CFL) with a novel LED white light source that is depleted in the short-wavelength visible range (Biological Illumination LCC, FL).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Visible light
Description: We will compare the effects of two light sources, equated for visual stimulus (lux), on multiple non-visual responses to light including melatonin suppression before bedtime. We will compare a 90 lux exposure of a commercially available Compact Fluorescent Light (CFL) with a novel LED white light source that is depleted in the short-wavelength visible range (Biological Illumination LCC, FL).